Key facts
- This page summarizes Stephen Basil Thomas's Form 4 filing for Eliem Therapeutics, Inc. (CLYM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Jun 2024, 19:03.
Stephen Basil Thomas - 27 Jun 2024 Form 4 Insider Report for Eliem Therapeutics, Inc. (CLYM)
- Reporting relationship
- Director
- Issuer ticker
- CLYM
- Reported as of
- 27 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2024, 19:03:48 UTC
- Next SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Emily Pimblett, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Basil Thomas filed Form 4 for Eliem Therapeutics, Inc. (CLYM) on 27 Jun 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELYM
transaction
Common Stock
Award
- Transaction value
- Shares
- +103,907
- Change %
- Price
- Shares after
- 103,907
- Date
- 27 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELYM
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +100,375
- Change %
- Price
- $0.000000
- Shares after
- 100,375
- Date
- 27 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,375
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting.
Footnote F3
The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.